Pictet Asset Management Holding SA Sells 20,270 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Pictet Asset Management sold 20,270 shares of Medpace, cutting its stake by 68.2% to 9,443 shares valued at $5.35 million as of the latest SEC filing.
• Multiple plaintiff firms have filed or are soliciting lead plaintiffs in a class action alleging securities-law violations after Medpace disclosed rising cancellations, increasing potential litigation, discovery and settlement risk for investors.
• Medpace beat quarterly estimates (EPS $4.28 vs. $3.74; revenue $706.6M vs. $697.8M) and issued FY2026 guidance of $16.68–17.50 EPS, though analysts maintain a consensus Hold rating with a $467.08 price target.

Pictet Asset Management Holding SA lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 68.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,443 shares of the company's stock after selling 20,270 shares during the period. Pictet Asset Management Holding SA's holdings in Medpace were worth $5,353,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. AQR Capital Management LLC boosted its holdings in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock worth $518,170,000 after buying an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Wasatch Advisors LP boosted its holdings in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Invesco Ltd. boosted its holdings in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company's stock worth $276,313,000 after buying an additional 85,517 shares during the last quarter. Finally, UBS Group AG boosted its holdings in Medpace by 32.8% during the fourth quarter. UBS Group AG now owns 328,879 shares of the company's stock worth $184,715,000 after buying an additional 81,250 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and set a $560.00 target price on the stock in a report on Friday, February 13th. BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a "market perform" rating for the company in a research report on Friday, April 24th. Weiss Ratings lowered Medpace from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, April 6th. TD Cowen upgraded Medpace from a "sell" rating to a "hold" rating and decreased their price objective for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, Royal Bank Of Canada decreased their price objective on Medpace from $522.00 to $484.00 and set an "outperform" rating for the company in a research report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $467.08.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Neutral Sentiment: Bares Capital trims its stake in Medpace, a portfolio move that may reflect manager rebalancing or concern about near-term risks. Bares Capital Trims Stake
• Negative Sentiment: A class action has been filed against Medpace and certain officers alleging violations of the federal securities laws for the period Apr 22, 2025–Feb 9, 2026; this formal filing increases legal exposure and investor uncertainty. Bronstein, Gewirtz & Grossman Class Action
• Negative Sentiment: Multiple plaintiff firms are actively soliciting lead plaintiffs and issuing investor alerts (Schall, Gross, BFA Law, Pomerantz, Rosen, Faruqi & Faruqi, Portnoy, Robbins, SueWallSt, Frank R. Cruz, Robbins LLP). The flurry of filings/solicitations heightens the probability of consolidated litigation, potential discovery, legal fees and settlement risk. Examples: Schall Law Firm Gross Law Firm BFA Law Pomerantz
• Negative Sentiment: Media coverage highlights that peers (Agios) posted strong results while reporting noted Medpace flagged rising cancellations—this operational disclosure appears to be the proximate cause of the stock weakness and underpins many litigation claims alleging the company misrepresented backlog/cancellation risks. Agios / Medpace Cancellations Coverage

Medpace Stock Performance

Shares of MEDP opened at $417.54 on Monday. The stock has a 50 day simple moving average of $468.91 and a 200 day simple moving average of $532.96. Medpace Holdings, Inc. has a 52-week low of $284.10 and a 52-week high of $628.92. The firm has a market capitalization of $11.92 billion, a PE ratio of 26.24, a P/E/G ratio of 2.12 and a beta of 1.19.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same period in the previous year, the firm earned $3.67 EPS. Medpace's quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 20.50% of the company's stock.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.